modelBenznidazole

Extends from Pharmacolibrary.Drugs.ATC.P.P01CA02.

Information

name:Benznidazole
ATC code:P01CA02
route:oral
compartments:1
dosage:100mg
volume of distribution:1.31L
clearance:116ml/min
other parameters in model implementation

Benznidazole is a nitroimidazole derivative antiprotozoal medication primarily used for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi. It is approved for use in several countries, including the United States, for both pediatric and adult patients.

Pharmacokinetics

Pharmacokinetic parameters observed in healthy adult volunteers following single oral administration.

References

  1. Altcheh, J, et al., & García-Bournissen, F (2014). Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS neglected tropical diseases 8(5) e2907–None. DOI:10.1371/journal.pntd.0002907 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24853169

  2. Del Moral Sanchez, JM, et al., & Bermejo, M (2018). Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system. British journal of clinical pharmacology 84(10) 2231–2241. DOI:10.1111/bcp.13650 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29846973

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)